Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy and Merck Pen R&D Deal; Ranbaxy Could See Six-Year Earnings Surge With Recent Collaborations

This article was originally published in PharmAsia News

Executive Summary

 

You may also be interested in...



"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 1 of 2)

Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.

"We Want To Shape Up Medical Treatment Paradigm Through Partnerships," Says Merck Asia-Pac President Ramesh Subrahmanian: An Interview With PharmAsia News (Part 1 of 2)

Merck Asia Pacific President of Human Health Ramesh Subrahmanian has been among the most energetic executives to have worked in the Indian pharmaceutical industry. Prior to serving in his present responsibilities, Subrahmanian worked for Sanofi-Aventis in several senior capacities - one of which was to head the company's Indian operations in 2000.

Orchid To Develop Merck’s Anti-Coagulant; To Buy Majority Stake In Diakron

MUMBAI - Chennai-based injectible cephalosporin manufacturer Orchid Chemicals will develop and manufacture an oral anti-coagulant drug that was initially discovered by U.S. drug maker Merck

Related Content

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel